Applicant, as named in the Orange Book

Priovant Therap

Next listed expiry: Lisraya on 19 Aug 2035. 1 products with live protection, 0 without.

Products with listed protection

Drug	Ingredient	NDA	Earliest generic entry	Basis
Lisraya brepocitinib tosylate	brepocitinib tosylate	220106	19 Aug 2035	patent

No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.